Basic Information

Common name
B-hCLDN18.2 BxPC-3
Catalog number
321827
Disease
Pancreatic adenocarcinoma
Organism
Human
Strain
Human
Tissue types
Pancreas
Tissue
Pancreas
Application
B-hCLDN18.2 BxPC-3 cells have the capability to establish tumors in vivo and can be used for efficacy studies.

Description

The exogenous promoter and human CLDN18.2 coding sequence were inserted into the BxPC-3 cells genome randomly. Human CLDN18.2 is highly expressed on the surface of B-hCLDN18.2 BxPC-3 cells.

Targeting strategy

Gene targeting strategy for B-hCLDN18.2 BxPC-3 cells. The exogenous promoter and human CLDN18.2 coding sequence were inserted into the BxPC-3 cells genome randomly.

Protein expression analysis

CLDN18.2 expression analysis in B-hCLDN18.2 BxPC-3 cells by flow cytometry. Single cell suspensions from B-hCLDN18.2 BxPC-3 cultures were stained with species-specific anti-CLDN18.2 antibody. Human CLDN18.2 was detected on the surface of B-hCLDN18.2 BxPC-3 cells. The 1-A04 clone of B-hCLDN18.2 BxPC-3 cells was used for in vivo experiments.

Tumor growth curve & Body weight changes

Subcutaneous homograft tumor growth of B-hCLDN18.2 BxPC-3 cells. B-hCLDN18.2 BxPC-3 cells (1×107) and wild-type BxPC-3 cells (1×107) were subcutaneously implanted into B-NDG mice (female, 9-week-old, n=5). Tumor volume and body weight were measured twice a week. (A) Average tumor volume ± SEM. (B) Body weight (Mean± SEM). Volume was expressed in mm3 using the formula: V=0.5 X long diameter X short diameter2. As shown in panel A, B-hCLDN18.2 BxPC-3 cells were able to establish tumors in vivo and can be used for efficacy studies.

Tumor volume and weight measurements

Protein expression analysis of tumor cells

B-hCLDN18.2 BxPC-3 cells were subcutaneously transplanted into B-NDG mice (n=5), and on 77 days post inoculation, tumor cells were harvested and assessed for human CLDN18.2 expression by flow cytometry. As shown, human CLDN18.2 was highly expressed on the surface of tumor cells. Therefore, B-hCLDN18.2 BxPC-3 cells can be used for in vivo efficacy studies of novel CLDN18.2 therapeutics.